Literature DB >> 2060518

Antistaphylococcal activity of the fluoroquinolones CI-960, PD 131628, sparfloxacin, ofloxacin and ciprofloxacin.

A L Barry1, P C Fuchs.   

Abstract

Five fluoroquinolones were tested against 300 staphylococci from a wide variety of US medical centers including 150 strains resistant to penicillinase-resistant penicillins (PRP-resistant). Ten ciprofloxacin-resistant strains of PRP-resistant Staphylococcus aureus were relatively resistant to the other fluoroquinolones, but the remaining 290 isolates were susceptible to all five drugs at established or anticipated breakpoint concentrations. The relative potency of the study drugs could be ranked as follows: CI-960 greater than PD 131628 greater than sparfloxacin greater than ciprofloxacin greater than ofloxacin. All five drugs were bactericidal against PRP-resistant and PRP-susceptible staphylococci.

Entities:  

Mesh：

Substances：

Year:  1991        PMID： 2060518     DOI： 10.1007/bf01964451

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN： 0934-9723            Impact factor:   3.267


  9 in total

1.  Ciprofloxacin-resistant methicillin-resistant Staphylococcus aureus in an acute-care hospital.

Authors:  M C Raviglione; J F Boyle; P Mariuz; A Pablos-Mendez; H Cortes; A Merlo
Journal:  Antimicrob Agents Chemother       Date:  1990-11       Impact factor: 5.191

2.  In vitro activity of AT-4140 against quinolone- and methicillin-resistant Staphylococcus aureus.

Authors:  T Kojima; M Inoue; S Mitsuhashi
Journal:  Antimicrob Agents Chemother       Date:  1990-06       Impact factor: 5.191

3.  In vitro antibacterial activities of PD 131628, a new 1,8-naphthyridine anti-infective agent.

Authors:  M A Cohen; M D Huband; G B Mailloux; S L Yoder; G E Roland; J M Domagala; C L Heifetz
Journal:  Antimicrob Agents Chemother       Date:  1991-01       Impact factor: 5.191

4.  The prevalence of staphylococcal resistance to penicillinase-resistant penicillins. A retrospective and prospective national surveillance trial of isolates from 40 medical centers.

Authors:  R N Jones; A L Barry; R V Gardiner; R R Packer
Journal:  Diagn Microbiol Infect Dis       Date:  1989 Sep-Oct       Impact factor: 2.803

5.  Method of reliable determination of minimal lethal antibiotic concentrations.

Authors:  R D Pearson; R T Steigbigel; H T Davis; S W Chapman
Journal:  Antimicrob Agents Chemother       Date:  1980-11       Impact factor: 5.191

6.  Increasing resistance of Staphylococcus aureus to ciprofloxacin.

Authors:  T E Daum; D R Schaberg; M S Terpenning; W S Sottile; C A Kauffman
Journal:  Antimicrob Agents Chemother       Date:  1990-09       Impact factor: 5.191

7.  Antistaphylococcal activities of sparfloxacin (CI-978; AT-4140), ofloxacin, and ciprofloxacin.

Authors:  A Z Chaudhry; C C Knapp; J Sierra-Madero; J A Washington
Journal:  Antimicrob Agents Chemother       Date:  1990-09       Impact factor: 5.191

8.  Comparative in vitro activity of PD 127,391, a new fluorinated 4-quinolone derivative.

Authors:  S R Norrby; M Jonsson
Journal:  Antimicrob Agents Chemother       Date:  1988-08       Impact factor: 5.191

9.  In vitro activity of ciprofloxacin against gram-positive cocci.

Authors:  A L Barry; R N Jones
Journal:  Am J Med       Date:  1987-04-27       Impact factor: 4.965
  9 in total
  6 in total

1.  Penetration of pefloxacin into maxillary sinus cavity and nasal secretions.

Authors:  G Petrikkos; P Goumas; E Moschovakis; H Giamarellou
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1992-09       Impact factor: 3.267

2.  Interpretive criteria and quality control parameters for testing bacterial susceptibility to the fluoroquinolone PD131628.

Authors:  A L Barry; P C Fuchs; S D Allen; F C Tenover; J H Jorgensen; L B Reller
Journal:  J Clin Microbiol       Date:  1995-01       Impact factor: 5.948

3.  CI-960, a new fluoroquinolone, for therapy of experimental ciprofloxacin-susceptible and -resistant Staphylococcus aureus endocarditis.

Authors:  G W Kaatz; S M Seo; K C Lamp; E M Bailey; M J Rybak
Journal:  Antimicrob Agents Chemother       Date:  1992-06       Impact factor: 5.191

4.  In vitro antistaphylococcal activities of two investigative fluoroquinolones, CI-960 and WIN 57273, compared with those of ciprofloxacin, mupirocin (pseudomonic acid), and peptide-class antimicrobial agents.

Authors:  K E Aldridge
Journal:  Antimicrob Agents Chemother       Date:  1992-04       Impact factor: 5.191

Review 5.  Ciprofloxacin. An updated review of its pharmacology, therapeutic efficacy and tolerability.

Authors:  R Davis; A Markham; J A Balfour
Journal:  Drugs       Date:  1996-06       Impact factor: 9.546

6.  In vitro evaluation of ABT-719, a novel DNA gyrase inhibitor.

Authors:  R K Flamm; C Vojtko; D T Chu; Q Li; J Beyer; D Hensey; N Ramer; J J Clement; S K Tanaka
Journal:  Antimicrob Agents Chemother       Date:  1995-04       Impact factor: 5.191
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.